chronic-kidney-disease
(2)Steve Steinberg
Steve Steinberg is a San Diego nephrologist who helped grow Balboa Nephrology Medical Group from a tiny two-physician practice into the largest nephrology group in California, now spanning roughly 60 board-certified nephrologists, dozens of clinical offices and scores of dialysis clinics. As CEO-Medical Director he has steered Balboa toward value-based kidney care, where the group posts some of the strongest national outcomes in CMS and CMMI programs, while championing the idea that kidney patients should never feel alone in their care.
Blaine McKee
Blaine McKee is the president and CEO of Walden Biosciences, a Cambridge, Massachusetts biotech building first-in-class medicines that go after the kidney itself instead of just slowing the road to dialysis. A chemist turned dealmaker turned operator, he launched Walden with a $51 million Series A in 2020 and now steers two clinical-stage programs: WAL0921, an anti-suPAR antibody, and WAL0623, a small-molecule dynamin stabilizer. Before Walden he spent 15 years at Genzyme and held top corporate-development roles at Shire and ImmunoGen, pairing an MIT organic-chemistry PhD with an MIT Sloan finance MBA.